PerpEquities

Equity · Healthcare

Iovance Biotherapeutics, Inc. (IOVA) perpetual futures

Iovance Biotherapeutics is a clinical-stage biotechnology company developing cancer immunotherapies that use a patient's own immune system, including lifileucel for advanced melanoma and LN-145 for head and neck cancer.

$6.91Market closed until the venue's next session · last quote Nov 20, 20:59 UTCNASDAQ closed
Open in terminal

Price chart

Interactive TradingView chart

TradingView symbol NASDAQ:IOVA

Loads TradingView's third-party widget (about 1 MB) on demand.

Auto: underlying reference priceOpen in TradingView

Trading data

Perpetual market activity

0/1 live markets
Venues
0
Live markets
0/1
24h volume
-
Open interest
-
Best liquidity
-
Tightest spread
-
Highest volume
-
Settlement mix
USDT · 1/1
Perp/spot vol.
-
Spot performance
1D-5.61%
5D-10.39%
1M-51.20%
6M+67.88%
YTD+152.75%
1Y+176.00%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BingXTradeIOVA-USDTWatchlist------USDT-
Best venues for this underlying

Best liquidity

-
No live data-

Tightest spread

-
No live data-

Highest volume

-
No live data-

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-11-05 · next report 2027-02-23 · Updated 5h ago
All financials →

Valuation & key figures

Market cap
$3.19B
Updated 5h ago
Revenue
$379M
Trailing 12 months
Revenue growth
+59%
FY2026 consensus
Profit margin
-58.2%
Net income / revenue, TTM
P/E
No P/E
Loss in the last twelve months
P/S
8.4×
Price / sales, TTM
Peer P/E
45.1×
Similar listed perps
EV / EBITDA
-17.1×
TTM
Free cash flow
-$216M
Trailing 12 months
Net income
-$221M
Trailing 12 months
Revenue estimate
$419M
FY2026 consensus
Earnings
2027-02-23
Revenue est. $128M · Updated 5h ago
Dividend
–
No dividend
Revenue (TTM)$379M+51.3% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)-60.8%+103.5 pp vs a year agoOperating income -$230M
Net income (TTM)-$221M+44.5% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)-$216M+38.6% vs a year agoCapex $26.1M
Diluted EPS (TTM)-$0.53+55.8% vs a year agoSum of the last 4 quarters
Net cash$331M+33.3% vs a year agoCash + short-term investments - debt
  • Last report (2026-11-05): revenue beat by 4.7%, EPS beat by 40.5%Revenue $121M vs $116M expected (+4.7%); EPS -$0.05 vs -$0.08 (+40.5%).
  • Revenue growth accelerating: 80.1% year on yearQ3 '26 revenue $121M, against an average of 35.9% over the four quarters before.
  • Operating margin -60.8% (TTM), +103.5 pp on a year agoOperating income grew 44.0% while revenue grew 51.3%.
  • Capex 6.9% of revenue (a year ago 11.5%)$26.1M invested in the last 4 quarters (-9.0% on a year earlier). Free cash flow -$216M.

Revenue, operating income and growth

quarterly
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 194 lines Iovance Biotherapeutics, Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-23
Revenue est. $128M · Updated 5h ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-0.38$418.6M+59%6
FY 2027-0.09$594.4M+42%6
FY 20280.28$864.4M+45%3
FY 20290.32$1.1B+25%1
FY 20300.59$1.4B+27%1
Q3 2026-0.08$116M+72%5
Source: FMP · Consensus

Company events

6
2027-02-23EarningsActual - / Estimate -0.07-
2026-11-05Earnings · Before market openActual -0.05 / Estimate -0.0841Beat
2026-08-06EarningsActual -0.11 / Estimate -0.133Beat
2026-05-07EarningsActual -0.19 / Estimate -0.19In line
2026-02-24EarningsActual -0.18 / Estimate -0.22Beat
2025-11-06EarningsActual -0.25 / Estimate -0.29Beat

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 21, 2026, 07:58 PM UTC

Company profile

Sector
Healthcare
Industry
Biotechnology
Chief executive
Frederick G. Vogt
Employees
975
IPO date
Oct 15, 2010
Country
US
Exchange
NASDAQ Global Market
Website
Altman Z-scorei8.16
Piotroski scorei4/9
Overall ratingiC
Owner earningsi$25.43M$0.06 per share
ESG risk ratingiBIndustry rank: 555/728

Rating factors

Return on equityi
1/5
Return on assetsi
1/5
Debt to equityi
4/5
Price to earningsi
1/5
Price to booki
3/5
Market cap history
$3.15B-15.7%Aug 2026 – Nov 2026
$3.15B$4.85B$6.55BHigh: $6.55B · 2026-10-12Latest: $3.15B · 2026-11-20Aug 2026Sep 2026Oct 2026Nov 2026
Latest: $3.15B · 2026-11-20High: $6.55B · 2026-10-12Low: $3.15B · 2026-11-20
Largest fund holders
FundWeightShares held
VTI0.01%13.5M
XBI1.04%12.1M
IWM0.11%10.1M
NJM0.04%7.9M
VB0.04%4.8M
VXF0.07%4.4M
FSSNX0.1%4.2M
IWN0.23%3.7M
FSMAX0.07%3.2M
IBB0.23%3.1M
NAJ0.08%2.9M
VTWO0.19%2.3M

Analyst track record

How the analysts covering IOVA have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings60220
Analysts1423
Buy / hold / sell49 / 10 / 1192 / 25 / 3
Upgrades / downgrades / initiations1 / 0 / 11 / 6 / 2
Price targets hit / missed10 / 47 (18%)29 / 167 (15%)
Avg. return after a rating (TipRanks)-21.7%-33.1%
Best / worst call+265.5% / -63.5%+631.0% / -78.5%

After buy calls on this stock: median 21-day move -4.6% vs S&P 500 -8.6% (n = 209)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Yanan ZhuWells Fargo17% hit rate on this stock · 18 targets measuredBuytarget $18.00Oct 29, 2026
  2. Joseph PantginisH.C. Wainwright14% hit rate on this stock · 21 targets measuredBuytarget $20.00Nov 11, 2026
  3. Colleen M. KusyRobert W. Baird0% hit rate on this stock · 10 targets measuredHoldtarget $9.00Oct 30, 2026

Latest ratings

DateAnalystCallTarget
Nov 20, 2026Salim SyedMizuho SecuritiesNov 20, 2026HoldDowngraded$7.00↗
Nov 11, 2026Joseph PantginisH.C. WainwrightNov 11, 2026BuyReiterated$20.00↗
Nov 6, 2026Reni BenjaminCitizens JMPNov 6, 2026BuyMaintained$12.00↗
Nov 6, 2026Etzer DaroutBarclaysNov 6, 2026BuyMaintained$19.00↗
Nov 5, 2026Joseph PantginisH.C. WainwrightNov 5, 2026BuyReiterated$20.00↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$2.00$4.00$6.00$8.00$10.00$12.00$14.00Dec 25 · Buy 6 · Hold 2 · Sell 1Dec 25Jan 26 · Buy 6 · Hold 1 · Sell 1Feb 26 · Buy 7 · Hold 2 · Sell 1Feb 26Mar 26 · Buy 8 · Hold 3 · Sell 1Apr 26 · Buy 8 · Hold 3 · Sell 1Apr 26May 26 · Buy 7 · Hold 3 · Sell 1Jun 26 · Buy 8 · Hold 3 · Sell 1Jun 26Jul 26 · Buy 8 · Hold 3 · Sell 1Aug 26 · Buy 8 · Hold 2 · Sell 0Aug 26Sep 26 · Buy 9 · Hold 2 · Sell 0Oct 26 · Buy 10 · Hold 2 · Sell 0Oct 26Nov 26 · Buy 8 · Hold 3 · Sell 0Dec 25 · avg. target $8.64Jan 26 · avg. target $8.64Feb 26 · avg. target $7.78Mar 26 · avg. target $7.64Apr 26 · avg. target $7.64May 26 · avg. target $7.80Jun 26 · avg. target $8.00Jul 26 · avg. target $8.00Aug 26 · avg. target $9.50Sep 26 · avg. target $12.45Oct 26 · avg. target $13.58Nov 26 · avg. target $13.73Dec 25 · month-end close $2.73Jan 26 · month-end close $2.55Feb 26 · month-end close $3.86Mar 26 · month-end close $3.51Apr 26 · month-end close $3.36May 26 · month-end close $4.10Jun 26 · month-end close $4.16Jul 26 · month-end close $4.07Aug 26 · month-end close $8.17Sep 26 · month-end close $14.82Oct 26 · month-end close $8.48Nov 26 · month-end close $6.90

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 21, 2026 · 60 ratings

Embed this asset

IOVA perpetuals · perpequities.comIOVA perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/iova-perp"><img src="https://perpequities.com/badge/iova-perp.svg" width="240" height="64" alt="IOVA perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of IOVA perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for IOVA — one email every Sunday.

Watchlist and alerts

Price and funding alerts for IOVA, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X